Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Dec 9

PMID 38067480

Authors

Lamei Guo

Jinjun Yang

Hao Wang

Yu Yi

Affiliations

Soon will be listed here.

Abstract

Advances in nanotechnology have brought innovations to cancer therapy. Nanoparticle-based anticancer drugs have achieved great success from bench to bedside. However, insufficient therapy efficacy due to various physiological barriers in the body remains a key challenge. To overcome these biological barriers and improve the therapeutic efficacy of cancers, multistage self-assembled nanomaterials with advantages of stimuli-responsiveness, programmable delivery, and immune modulations provide great opportunities. In this review, we describe the typical biological barriers for nanomedicines, discuss the recent achievements of multistage self-assembled nanomaterials for stimuli-responsive drug delivery, highlighting the programmable delivery nanomaterials, in situ transformable self-assembled nanomaterials, and immune-reprogramming nanomaterials. Ultimately, we perspective the future opportunities and challenges of multistage self-assembled nanomaterials for cancer immunotherapy.

Citing Articles

Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.

Yun Y, Kim S, Lee S, Cho H, Choi J Nano Converg. 2024; 11(1):56.

PMID: 39671082 PMC: 11645384. DOI: 10.1186/s40580-024-00466-x.

Nanomedicine for cancer patient-centered care.

Sorrentino C, Ciummo S, Fieni C, Di Carlo E MedComm (2020). 2024; 5(11):e767.

PMID: 39434967 PMC: 11491554. DOI: 10.1002/mco2.767.

References

Zeng Z, Zhang C, Li J, Cui D, Jiang Y, Pu K . Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy. Adv Mater. 2020; 33(4):e2007247. DOI: 10.1002/adma.202007247. View

Li W, Liu Z, Fontana F, Ding Y, Liu D, Hirvonen J . Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy. Adv Mater. 2018; 30(24):e1703740. DOI: 10.1002/adma.201703740. View

Yu H, De Geest B . Nanomedicine and cancer immunotherapy. Acta Pharmacol Sin. 2020; 41(7):879-880. PMC: 7471393. DOI: 10.1038/s41401-020-0426-2. View

Dai Y, Xu C, Sun X, Chen X . Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017; 46(12):3830-3852. PMC: 5521825. DOI: 10.1039/c6cs00592f. View

Chen B, Dai W, He B, Zhang H, Wang X, Wang Y . Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics. 2017; 7(3):538-558. PMC: 5327631. DOI: 10.7150/thno.16684. View

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H . In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018; 14(1):89-97. DOI: 10.1038/s41565-018-0319-4. View

Xue X, Qu H, Li Y . Stimuli-responsive crosslinked nanomedicine for cancer treatment. Exploration (Beijing). 2023; 2(6):20210134. PMC: 10190936. DOI: 10.1002/EXP.20210134. View

Xu J, Song M, Fang Z, Zheng L, Huang X, Liu K . Applications and challenges of ultra-small particle size nanoparticles in tumor therapy. J Control Release. 2022; 353:699-712. DOI: 10.1016/j.jconrel.2022.12.028. View

Li T, Pan S, Gao S, Xiang W, Sun C, Cao W . Diselenide-Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies. Angew Chem Int Ed Engl. 2019; 59(7):2700-2704. DOI: 10.1002/anie.201914453. View

10.

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

11.

Bockamp E, Rosigkeit S, Siegl D, Schuppan D . Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. Cells. 2020; 9(9). PMC: 7565449. DOI: 10.3390/cells9092102. View

12.

Alshaer W, Hillaireau H, Fattal E . Aptamer-guided nanomedicines for anticancer drug delivery. Adv Drug Deliv Rev. 2018; 134:122-137. DOI: 10.1016/j.addr.2018.09.011. View

13.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

14.

Obradovic A . Precision immunotherapy. Science. 2023; 379(6633):654-655. DOI: 10.1126/science.adg5585. View

15.

Najjar A, Najjar A, Karaman R . Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years. Molecules. 2020; 25(4). PMC: 7070911. DOI: 10.3390/molecules25040884. View

16.

Boissenot T, Bordat A, Fattal E, Tsapis N . Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications. J Control Release. 2016; 241:144-163. DOI: 10.1016/j.jconrel.2016.09.026. View

17.

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

18.

Yi Y, An H, Wang H . Intelligent Biomaterialomics: Molecular Design, Manufacturing, and Biomedical Applications. Adv Mater. 2023; 36(22):e2305099. DOI: 10.1002/adma.202305099. View

19.

Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z . Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023; 8(1):124. PMC: 10017761. DOI: 10.1038/s41392-023-01382-y. View

20.

Su L, Feng Y, Wei K, Xu X, Liu R, Chen G . Carbohydrate-Based Macromolecular Biomaterials. Chem Rev. 2021; 121(18):10950-11029. DOI: 10.1021/acs.chemrev.0c01338. View